Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced on Wednesday that it has signed a Master Partnership Agreement (MPA) with Taiwan-based animal vaccine development and distribution company Reber Genetics (Chairman Sunny Kang) to collaborate on the technology transfer and commercialization of companion animal healthcare products.

The agreement establishes a comprehensive framework governing future technology transfer arrangements as well as product export and supply agreements between the two companies. Under the partnership, the companies will work together to obtain regulatory approvals and advance commercialization in key Asian markets, including Taiwan, Thailand, and Vietnam. Vaxcellbio will provide relevant technologies and product pipeline assets, while Reber Genetics will oversee country-specific regulatory processes, local distribution, and commercialization activities.

Based on this MPA, the companies plan to pursue technology transfer collaboration for Vaxleukin-15 Inj., an immune-based therapy for companion animals, while also advancing the export and local commercialization of Goldmmune, an immune-function supplement, and Vaxsure, an immune-based companion animal healthcare product. Through the agreement, Vaxcellbio is expected to accelerate the overseas expansion of its key companion animal healthcare pipeline.

Reber Genetics specializes in the development and commercialization of genetic- and immune-based animal healthcare solutions and has built a strong global business network across Asia supported by established regulatory and distribution capabilities. Through this collaboration, Reber Genetics will expand its portfolio of immune-based animal healthcare products, while Vaxcellbio will leverage Reber Genetics’ local commercialization expertise to progressively broaden its presence in overseas markets.

“This Master Partnership Agreement will serve as a strategic foothold for expanding our technological competitiveness in companion animal immunotherapy and healthcare beyond Asia and into the global market,” said Je-Jung Lee, CEO of Vaxcellbio. “Through key products such as Vaxleukin-15, Goldmmune, and Vaxsure, we aim to achieve meaningful outcomes in the Asian companion animal healthcare market.”

Sunny Kang, Chairman of Reber Genetics, stated, “Vaxcellbio’s immune-based technologies hold strong potential in the companion animal healthcare sector. Through this collaboration, we expect to introduce differentiated companion animal healthcare solutions to Asian markets, starting with Taiwan.”

Building on this partnership, Vaxcellbio plans to sequentially conclude technology transfer agreements and product export and supply agreements, further expanding its presence in the global companion animal healthcare market.

Key Takeaways

• Vaxcellbio has signed a Master Partnership Agreement (MPA) with Taiwan’s Reber Genetics to advance technology transfer and commercialization of companion animal healthcare products, with Reber Genetics leading regulatory approvals and market development in Taiwan, Thailand, and Vietnam.
• The partnership will support the global expansion of Vaxcellbio’s companion animal healthcare pipeline, including Vaxleukin-15 Inj., Goldmmune, and Vaxsure, by leveraging Reber Genetics’ established regulatory expertise, distribution channels, and business network across Asia.
• “This Master Partnership Agreement will serve as a strategic foothold for expanding our technological competitiveness in companion animal immunotherapy and healthcare beyond Asia and into the global market,” said Je-Jung Lee, CEO of Vaxcellbio. “Through key products such as Vaxleukin-15, Goldmmune, and Vaxsure, we aim to achieve meaningful outcomes in the Asian companion animal healthcare market.
• Sunny Kang, Chairman of Reber Genetics, stated, “Vaxcellbio’s immune-based technologies hold strong potential in the companion animal healthcare sector. Through this collaboration, we expect to introduce differentiated companion animal healthcare solutions to Asian markets, starting with Taiwan.”